NASDAQ · DGX
Healthcare · Medical - Diagnostics & Research
$233.00
Up+$3.24 (+1.39%)
Updated Sep 24, 2026, 7:21 PM
SID Score
6.7/10
Composite research score
Smart Money
47/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DGX closed at $233.00 after 20 trading sessions, down 4.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 23, 2026 | $235.12 | $238.62 | $231.9225 | $233.00 | 1.13M |
| Sep 22, 2026 | $228.59 | $237.285 | $227.24 | $234.76 | 2.72M |
| Sep 21, 2026 | $247.13 | $248.84 | $243.93 | $244.88 | 907.61K |
| Sep 18, 2026 | $246.52 | $247.625 | $244.89 | $246.45 | 1.93M |
| Sep 17, 2026 | $248.28 | $248.695 | $246.26 | $247.45 | 989.5K |
| Sep 16, 2026 | $245.47 | $248.57 | $244.85 | $247.08 | 948.75K |
| Sep 15, 2026 | $238.39 | $248.65 | $237.21 | $247.08 | 1.37M |
| Sep 14, 2026 | $237.49 | $239.78 | $234.67 | $237.89 | 974.85K |
| Sep 11, 2026 | $233.20 | $235.12 | $229.33 | $235.02 | 997.03K |
| Sep 10, 2026 | $236.32 | $236.475 | $228.57 | $231.14 | 1.09M |
| Sep 9, 2026 | $233.58 | $236.24 | $232.43 | $235.46 | 791.15K |
| Sep 8, 2026 | $233.61 | $237.555 | $231.524 | $235.50 | 728.94K |
| Sep 4, 2026 | $235.38 | $238.915 | $235.38 | $237.14 | 798.7K |
| Sep 3, 2026 | $242.00 | $242.00 | $236.35 | $239.40 | 1.04M |
| Sep 2, 2026 | $238.03 | $242.835 | $236.27 | $240.80 | 1.14M |
| Sep 1, 2026 | $242.72 | $243.72 | $235.625 | $236.22 | 813.39K |
| Aug 31, 2026 | $241.99 | $242.635 | $239.40 | $240.30 | 1.36M |
| Aug 28, 2026 | $245.17 | $245.28 | $242.27 | $242.76 | 639.94K |
| Aug 27, 2026 | $242.83 | $247.19 | $242.44 | $244.61 | 839.99K |
| Aug 26, 2026 | $244.11 | $246.00 | $243.485 | $245.00 | 811.02K |
The latest Smart Investors Daily articles mentioning DGX.
DGX research
Company profile and research snapshot.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | Truist Securities | Hold | — |
| Sep 8, 2026 | UBS | Neutral | — |
| Jul 28, 2026 | JP Morgan | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | Baird | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 16, 2026
A new national survey finds the overwhelming majority of American voters rely on diagnostic laboratory testing to guide their healthcare decisions and are deeply concerned about scheduled Medicare payment cuts that could put that access at risk.
SeekingAlpha · Sep 15, 2026
Quest Diagnostics Incorporated (DGX) 2026 Global Healthcare Conference September 15, 2026 10:50 AM EDTCompany ParticipantsJames Davis - Chairman, CEO &...
SeekingAlpha · Sep 14, 2026
Quest Diagnostics Incorporated (DGX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsSam Samad -...
Yahoo · Sep 9, 2026
Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DGX.
